The double face of IL-1β in lung cancer

作者：Cédric Rébé, Anaïs Perrichet, François Ghiringhelli · 发表于：OncoImmunology · 年份：2026 · DOI：10.1080/2162402x.2026.2622661 · 研究领域：Immune Response and Inflammation、Inflammasome and immune disorders、IL-33, ST2, and ILC Pathways

Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.